GFI1 and acute myeloid leukemia: Moreover, knock down of Gfi1 provided a survival advantage to MLL-AF9 and NUP98-HOXD13 leukaemic mice, suggesting that targeting of Gfi1, could represent a new therapeutic strategy to inhibit stroma-driven disease mechanisms in AML.